The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence

Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution

(2011) Philippe Metellus et al.   ANNALS OF SURGICAL ONCOLOGY

An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma

(2011) Junjie Feng et al.   CANCER

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas

(2011) Ichiyo Shibahara et al.   International Journal of Clinical Oncology

Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial

(2011) Christian Senft et al.   LANCET ONCOLOGY

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab

(2011) W. B. Pope et al.   NEUROLOGY

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis

(2010) Roberto Pallini et al.   CANCER

Transcriptional Profiles of CD133+ and CD133- Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

(2010) C. Lottaz et al.   CANCER RESEARCH

O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma

(2010) Yukihiko Sonoda et al.   International Journal of Clinical Oncology

Radiographic patterns of relapse in glioblastoma

(2010) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Marker-independent identification of glioma-initiating cells

(2010) Virginie Clément et al.   NATURE METHODS

Association of stem cell marker CD133 expression with dissemination of glioblastomas

(2010) Atsushi Sato et al.   NEUROSURGICAL REVIEW

Long-term survivors of glioblastoma: clinical features and molecular analysis

(2009) Yukihiko Sonoda et al.   ACTA NEUROCHIRURGICA

Analysis ofIDH1andIDH2mutations in Japanese glioma patients

(2009) Yukihiko Sonoda et al.   CANCER SCIENCE

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status

(2009) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients

(2008) F. Zeppernick et al.   CLINICAL CANCER RESEARCH

Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

(2008) Anastasia Murat et al.   JOURNAL OF CLINICAL ONCOLOGY

Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients

(2008) Mingyu Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas

(2008) Kyeung Min Joo et al.   LABORATORY INVESTIGATION

A novel tool to analyze MRI recurrence patterns in glioblastoma

(2008) Wolfgang Wick et al.   NEURO-ONCOLOGY

Functional Outcome after Language Mapping for Glioma Resection

(2008) Nader Sanai et al.   NEW ENGLAND JOURNAL OF MEDICINE